Merck’s Garasil vaccine, promoted to prevent cervical cancer and genital warts, roared onto the market in 2006, but since then has decelerated sharply. Merck has been lobbying to increase its potential market to boys and mature women. It failed to persuade FDA to broaden use to older women–up to the age of 45–but now has convinced an agency advisory committee that Gardasil would be useful for boys and young men.
Fresh controversies are heating up over the marketing of products to prevent cervical cancer The U.S. Food & Drug Administration is gearing up to make critical decisions about two controversial vaccines. On Sept. 9 an FDA advisory committee will consider whether Merck (MRK)’s Gardasil, given to girls to prevent cancer-causing human papilloma virus (HPV), should [...]
I received an email from my ICAP associate, Christina England today. Her message explained a mystery I have been trying to solve for the past week. My site stats have indicated a large number of hits from Russian ISPs and those visitors spending time investigating my article archive. Christina noted the same site visitor anomalies and traced the traffic back to http://www.oodvrs.ru/article/index.php?id_page=47&id_article=940 and found her article about ICAP communications with the German Scientists of RKI concerning the safety of the HPV vaccines Gardasil and Cervarix. This article tracks back to our papers. It is amazing but our message has been have been translated into Russian. The word is getting out there yippee! Congrats to Christina!
The Society of Gynecologic Oncologists (SGO) has published the first in a series of four papers on a variety of cervical cancer issues and topics that were the focus of its Forum “The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare,” held last September in Chicago, Illinois.
State mandated Gardasil shots for preteen girls to protect them from the viruses that causes cervical cancer, are targeting the wrong age group. Middle-school girls inoculated with the HPV vaccine will be no older than eighteen when they pass Gardasil’s five-year window of proven effectiveness — more than a decade before the typical cancer patient contracts the sexually transmitted human papillomavirus (HPV). Merck & Co. has repeatedly refused to respond to requests for its HPV incubation statistics, stating that it is still studying the longevity of Gardasil.
FDA recommends that consumers stop using these products and throw them away
On June 16, 2009 The FDA issued the following product recall. The recall was triggered when the FDA received more than 130 reports of anosmia associated with the use of Zicam zinc-containing intranasal products. FDA is alerting consumers that Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Nasal Swabs, and Zicam Cold Remedy Swabs, Kids Size, a discontinued product that consumers may still have in their homes, have all been associated with long lasting or permanent loss of smell (referred to as anosmia).
The Gardasil issues I researched were the relatively limited trial period, the sketchy trail data; the cost benefit of a drug that was design to prevent a cancer that has been declining in both incidence and mortality for over 40-years. Cervical cancer is easily detected by regular PAP screening and in the early stages, the most treatable cancer. The other aspect of Gardasil roll-up that didn’t pass the smell test was the Merck Marauder School of lobbying today for a more profitable tomorrow. Merck literally carpet-bombed the halls of power and influence with cash to get GARDASIL approved by the FDA (while holding up the Glaxo HPV-vaccine, Cervarix), they got Gardasil endorsed by the CDC and mandated in many states as yet another vaccine necessary to attend school, and managed to get state legislators to pass bills to force insurance companies to pay for the Gardasil shot. As I researched the payouts and pay offs of state, local and federal representatives, I asked when did safety go on sale? Then I found out about Merck paying doctors to go on the stump to endorse Gardasil. Some docs with great speaking skills picked up several hundred thousand dollars in a year. Then there was the scandal about “Medical Journal-Like’ publications written by ‘bought and paid for’ doctors who dutifully regurgitated the WORD according to Merck.
The study was conducted in Australia, in 2007 and reported in The British Medical Journal in Dec 2008. Sharon Choo of the Royal Children’s Hospital in Melbourne reported that during 2007 more than 380,000 doses of the vaccine had been administered in schools in Victoria and South Australia under the Australian immunization program. Choo and colleagues noted some components of Merck’s treatment — such as aluminum salts and yeast — have been associated with allergic reactions. In the British Medical Journal article, published in late 2008, she and her colleges are quoted as saying, “Our clinical recommendation is that females with suspected hypersensitivity to the quadrivalent vaccine should be evaluated before receiving more doses, and any challenges with the same vaccine should be carried out in a supervised setting.”
Netherlands-based advocates, Janny Stokvis and Annelies Witlam have worked tirelessly to distribute the HPV-vaccine research paper produced by International Coalition of Advocates For The People and submitted to the Robert Koch Institute for review. They have supported the HPV-vaccine education process in the Netherlands, the UK, EU Canada and America and are founding members of the International Coalition of Advocates For The People (ICAP). I am proud to be counted amongst their professional associates.
All around the world concerns are mounting about the effectiveness and the safety of the HPV vaccines. Whilst many of our Governments refuse to listen to public concern and ignore the ever increasing numbers of children who have had adverse reactions to the Gardasil and Cervarix vaccines, in Germany their concerns are at last being looked at and examined carefully. The Robert Koch Institute in Germany which makes recommendations on the public funding of vaccines, is reviewing its vaccination programme after 13 experts called for a reassessment of its HPV vaccination programme and an end to “misleading information” about the effectiveness of the HPV-vaccine.
© 2002- An Inconvenient Woman. Site design and construction by Pleiades Publishing Services, Co.
Powered by Wordpress and based on the template design MyJournal Hypereal by 
BlogoSquare
